U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Non-cutaneous melanoma

MedGen UID:
233761
•Concept ID:
C1334974
•
Neoplastic Process
Synonyms: Extracutaneous Melanoma; extracutaneous melanoma; Non-Cutaneous Melanoma; non-cutaneous melanoma
 
Monarch Initiative: MONDO:0006320

Definition

A melanoma that arises from a site other than skin. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVNon-cutaneous melanoma

Professional guidelines

PubMed

Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255
Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma.
Veness MJ
Australas Radiol 2005 Oct;49(5):365-76. doi: 10.1111/j.1440-1673.2005.01496.x. PMID: 16174174

Recent clinical studies

Etiology

Vulvar Melanoma in association with germline MITF p.E318K variant.
Koeller DR, Schwartz A, DeSimone MS, Rana HQ, Rojas-Rudilla V, Russell-Goldman E, Laga AC, Lindeman NI, Garber JE, Ghazani AA
Cancer Genet 2022 Apr;262-263:102-106. Epub 2022 Feb 15 doi: 10.1016/j.cancergen.2022.02.003. PMID: 35220194
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Clinico-pathological Characteristics of Cutaneous Malignant Melanoma in Pakistan.
Khan RS, Shakeel O, Bhatti AF, Hussain R
J Coll Physicians Surg Pak 2020 Nov;30(11):1197-1200. doi: 10.29271/jcpsp.2020.11.1197. PMID: 33222740
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255

Diagnosis

Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape.
Vergara IA, Wilmott JS, Long GV, Scolyer RA
Exp Dermatol 2022 Jan;31(1):13-30. Epub 2021 Feb 1 doi: 10.1111/exd.14287. PMID: 33455025
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Clinico-pathological Characteristics of Cutaneous Malignant Melanoma in Pakistan.
Khan RS, Shakeel O, Bhatti AF, Hussain R
J Coll Physicians Surg Pak 2020 Nov;30(11):1197-1200. doi: 10.29271/jcpsp.2020.11.1197. PMID: 33222740
Risk factors, clinical outcomes, and natural history of uveal melanoma: a single-institution analysis.
Delgado-Ramos GM, Thomas F, VanderWalde A, King B, Wilson M, Pallera AM
Med Oncol 2019 Jan 21;36(2):17. doi: 10.1007/s12032-018-1230-4. PMID: 30666496
Diagnostic utility of EWS break-apart fluorescence in situ hybridization in distinguishing between non-cutaneous melanoma and clear cell sarcoma.
Song JS, Choi J, Kim JH, Jang SJ, Cho KJ
Pathol Int 2010 Sep;60(9):608-13. doi: 10.1111/j.1440-1827.2010.02570.x. PMID: 20712646

Therapy

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE, Stukalin I, Ding PQ, Goutam S, Sander M, Ewanchuk B, Cheung WY, Heng DYC, Cheng T
Curr Oncol 2023 Sep 30;30(10):8936-8947. doi: 10.3390/curroncol30100646. PMID: 37887546Free PMC Article
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255

Prognosis

Clinical features and response to systemic therapy in NRAS-mutant Chinese melanoma patients.
Wang J, Jiang H, Huang F, Li D, Wen X, Ding Q, Ding Y, Zhang X, Li J
J Cancer Res Clin Oncol 2023 Feb;149(2):701-708. Epub 2022 Dec 1 doi: 10.1007/s00432-022-04377-4. PMID: 36454283
Vulvar Melanoma in association with germline MITF p.E318K variant.
Koeller DR, Schwartz A, DeSimone MS, Rana HQ, Rojas-Rudilla V, Russell-Goldman E, Laga AC, Lindeman NI, Garber JE, Ghazani AA
Cancer Genet 2022 Apr;262-263:102-106. Epub 2022 Feb 15 doi: 10.1016/j.cancergen.2022.02.003. PMID: 35220194
Adjuvant systemic treatment for high-risk resected non-cutaneous melanomas: What is the evidence?
Tapia Rico G, Yong CH, Herrera Gómez RG
Crit Rev Oncol Hematol 2021 Nov;167:103503. Epub 2021 Oct 14 doi: 10.1016/j.critrevonc.2021.103503. PMID: 34656746
Clinico-pathological Characteristics of Cutaneous Malignant Melanoma in Pakistan.
Khan RS, Shakeel O, Bhatti AF, Hussain R
J Coll Physicians Surg Pak 2020 Nov;30(11):1197-1200. doi: 10.29271/jcpsp.2020.11.1197. PMID: 33222740
Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C
Curr Cancer Drug Targets 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714. PMID: 28183255

Clinical prediction guides

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE, Stukalin I, Ding PQ, Goutam S, Sander M, Ewanchuk B, Cheung WY, Heng DYC, Cheng T
Curr Oncol 2023 Sep 30;30(10):8936-8947. doi: 10.3390/curroncol30100646. PMID: 37887546Free PMC Article
Vulvar Melanoma in association with germline MITF p.E318K variant.
Koeller DR, Schwartz A, DeSimone MS, Rana HQ, Rojas-Rudilla V, Russell-Goldman E, Laga AC, Lindeman NI, Garber JE, Ghazani AA
Cancer Genet 2022 Apr;262-263:102-106. Epub 2022 Feb 15 doi: 10.1016/j.cancergen.2022.02.003. PMID: 35220194
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S, Demidov L, Moiseyenko V, Protsenko S, Semiglazova T, Odintsova S, Zukov R, Lazarev S, Makarova Y, Nechaeva M, Sakaeva D, Andreev A, Tarasova A, Fadeyeva N, Shustova M, Kuryshev I
Eur J Cancer 2021 May;149:222-232. Epub 2021 Apr 17 doi: 10.1016/j.ejca.2021.02.030. PMID: 33872982
Clinico-pathological Characteristics of Cutaneous Malignant Melanoma in Pakistan.
Khan RS, Shakeel O, Bhatti AF, Hussain R
J Coll Physicians Surg Pak 2020 Nov;30(11):1197-1200. doi: 10.29271/jcpsp.2020.11.1197. PMID: 33222740
Risk factors, clinical outcomes, and natural history of uveal melanoma: a single-institution analysis.
Delgado-Ramos GM, Thomas F, VanderWalde A, King B, Wilson M, Pallera AM
Med Oncol 2019 Jan 21;36(2):17. doi: 10.1007/s12032-018-1230-4. PMID: 30666496

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...